Ueda, N.; Kuroki, M.; Shibata, H.; Matsubara, M.; Akita, S.; Yamada, T.; Kato, R.; Iinuma, R.; Kawaura, R.; Okuda, H.;
et al. Immune-Modified Glasgow Prognostic Score Predicts Therapeutic Effect of Pembrolizumab in Recurrent and Metastatic Head and Neck Cancer. Cancers 2024, 16, 4056.
https://doi.org/10.3390/cancers16234056
AMA Style
Ueda N, Kuroki M, Shibata H, Matsubara M, Akita S, Yamada T, Kato R, Iinuma R, Kawaura R, Okuda H,
et al. Immune-Modified Glasgow Prognostic Score Predicts Therapeutic Effect of Pembrolizumab in Recurrent and Metastatic Head and Neck Cancer. Cancers. 2024; 16(23):4056.
https://doi.org/10.3390/cancers16234056
Chicago/Turabian Style
Ueda, Natsuko, Masashi Kuroki, Hirofumi Shibata, Manato Matsubara, Saki Akita, Tatsuhiko Yamada, Rina Kato, Ryota Iinuma, Ryo Kawaura, Hiroshi Okuda,
and et al. 2024. "Immune-Modified Glasgow Prognostic Score Predicts Therapeutic Effect of Pembrolizumab in Recurrent and Metastatic Head and Neck Cancer" Cancers 16, no. 23: 4056.
https://doi.org/10.3390/cancers16234056
APA Style
Ueda, N., Kuroki, M., Shibata, H., Matsubara, M., Akita, S., Yamada, T., Kato, R., Iinuma, R., Kawaura, R., Okuda, H., Terazawa, K., Mori, K., Saijo, K., Ohashi, T., & Ogawa, T.
(2024). Immune-Modified Glasgow Prognostic Score Predicts Therapeutic Effect of Pembrolizumab in Recurrent and Metastatic Head and Neck Cancer. Cancers, 16(23), 4056.
https://doi.org/10.3390/cancers16234056
